Role of oral anticoagulants in patients after an acute coronary syndrome.

Abstract

After an acute coronary syndrome, patients continue to be at risk of adverse cardiovascular events despite treatment with the current standard of antithrombotic therapy. The risk may be in part secondary to thrombin, which remains elevated after an acute coronary syndrome event. Several studies have investigated the utility of adding oral anticoagulation to post-acute coronary syndrome medical regimens, with the most promising results coming from the addition of low-dose oral direct anticoagulants. Focusing on optimal dosing strategies and applying therapies to the appropriate populations provide the ability to maximize benefit and minimize risk.

• Authors: Edward T Carreras, Jessica L Mega
• Journal: Arteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol) Vol. 35 Issue 3 Pg. 520-4 (Mar 2015) ISSN: 1524-4636 [Electronic] United States
• PMID: 25614282 (Publication Type: Journal Article, Review)
• Copyright: © 2015 American Heart Association, Inc.

Chemical References

• Anticoagulants
• Fibrinolytic Agents
• Platelet Aggregation Inhibitors

Topics

• Acute Coronary Syndrome (blood, drug therapy, physiopathology)
• Administration, Oral
• Anticoagulants (administration & dosage, adverse effects)
• Drug Dosage Calculations
• Drug Therapy, Combination
• Fibrinolytic Agents (administration & dosage, adverse effects)
• Humans
• Platelet Aggregation Inhibitors (administration & dosage)
• Risk Factors
• Treatment Outcome